IL-PROJECT44
11.6.2020 13:02:07 CEST | Business Wire | Press release
project44 , the global leader in advanced visibility for shippers and logistics service providers, today announced the industry’s first Global Preferred Carriers Program . This program evaluates and recognizes — through a monthly published list — less-than-truckload (LTL) and truckload carriers in the project44 network that have demonstrated excellence in performance, consistency, delivery of high-fidelity data and shipment visibility across multiple loads.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200611005018/en/
Through this program, global retailers, manufacturers and distributors can benefit from more predictable and higher service levels and increased network stability. Preferred carriers have the advantage of gaining additional business opportunities from over 300 enterprise customers, representing $57B of managed freight, and more strategic, multiyear relationships.
“Markets will always have their ups and downs, and we have to stay agile and productive regardless. Real-time visibility empowers us to add more value to our customers by keeping their costs consistent and shipments predictable,” said Bartłomiej Wędzikowski of Wedzikowski Transport, a leading European truckload carrier headquartered in Poland. “We’re confident that our standing in project44’s Preferred Carriers list will send a direct signal to our customers that we are committed to their business success.”
project44 Preferred Carriers include 9 LTL carriers in North America and 320 truckload carriers, including Top200 in Europe, Top100 in North America, and Top20 in Latin America. Each of these 329 carriers demonstrated best in class performance levels and exceeded their customers’ expectations for real-time visibility.
Those included on the list are awarded with the tracking compliance badge representing that a particular carrier has met project44’s rigorous tracking standards, including high tracking percentages across multiple loads, consistent delivery of high-fidelity data, and commitment to real-time shipment visibility. Some of the pioneering carriers reaching Preferred status in May include Saia and Averitt Express on the LTL list and DSV and CR England on the truckload list.
“project44 enables LTL carriers to eliminate manual processes and increase efficiency,” said Marek Bella, leader of Europe Carrier Operations at project44. “Our data shows that truckload carriers visible on the project44 network are four times more likely to win freight and new customers.”
“We’re very proud to be recognized as a project44 Preferred Carrier. Capacity is tight, and trucking conditions have been changed dramatically and rapidly,” said Wendi Fitzsimmons, Project and IT Manager at Volpe Dedicated, a North American carrier with nearly 100 years of truckload experience. “With a streamlined data sharing process, we were able to provide a competitive customer experience by balancing pricing and on-time delivery. As a result, we’re equipped to bypass transactional interactions and invest our resources in building long-term strategic partnerships with our customers.”
“Our customer’s experience is central to our roadmap and DNA,” said Tommy Barnes, Head of Global Network Partnerships at project44. “By introducing the first global Preferred Carriers program, we want to help the entire transportation ecosystem drive more operational efficiencies and delivery excellence within the entire supply chain.”
To usher in a new era of trust and predictability, project44 has built the most expansive multimodal network, five times larger than any other visibility provider. With the recent launch of the industry’s first and only unified multimodal visibility offering , frictionless collaboration and fast time to value has become a reality.
Learn more about project44 or schedule a demo today.
About project44
project44 is the world’s leading advanced visibility platform for shippers and logistics service providers. project44 connects, automates, and provides visibility into key transportation processes to accelerate insights and shorten the time it takes to turn those insights into actions. Leveraging the power of the project44 cloud-based platform, organizations increase operational efficiencies, reduce costs, improve shipping performance, and deliver an exceptional Amazon-like experience to their customers. Connected to thousands of carriers worldwide and having comprehensive coverage for all ELD and telematics devices on the market, project44 supports all transportation modes and shipping types, including Air, Parcel, Final-Mile, Less-than-Truckload, Volume Less-than-Truckload, Groupage, Truckload, Rail, Intermodal, and Ocean. project44 has placed second, behind only Amazon, on FreightWaves’ 2020 Freight Tech 25, a list of the most innovative companies across the freight industry, and received the 2020 SAP® Pinnacle Award as the Cloud Partner Integration of the Year. To learn more, visit www.project44.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200611005018/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
Beerenberg Prevails in Patent Case Against Aspen Aerogels29.6.2026 07:00:00 CEST | Press release
The ruling confirms that Beerenberg did not infringe Aspen Aerogels’ patents. The Korean Patent Court has invalidated three of Aspen Aerogels’ patents related to improved hydrophobic aerogel material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260628192007/en/ Beerenberg delivers high-end insulation solutions built for performance, reliability, and long-term value. (Photo: Beerenberg) The ruling confirms the conclusion of the Intellectual Property Trial and Appeal Board (IPTAB) that the patents did not meet the necessary requirements for patentability. Beerenberg, which specializes in high-end insulation products, welcomes the court’s decision. “We are pleased that the case has now been concluded and that any uncertainty regarding the infringement claims has been removed,” says CEO Arild Apelthun. About Beerenberg Beerenberg has delivered cost-efficient solutions to a wide range of industrial enterprises for 49 years. Th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
